

Vincent C O Njar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8440620/publications.pdf>

Version: 2024-02-01

86
papers

8,917
citations

117571

34
h-index

54882

84
g-index

92
all docs

92
docs citations

92
times ranked

17424
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
2	Regulation of androgen receptor activity by tyrosine phosphorylation. <i>Cancer Cell</i> , 2006, 10, 309-319.	7.7	325
3	Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens: Synthesis, in Vitro Biological Activity, Pharmacokinetics, and Antitumor Activity in the LAPC4 Human Prostate Cancer Xenograft Model. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 2972-2984.	2.9	228
4	Targeting cytochrome P450 enzymes: A new approach in anti-cancer drug development. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 5047-5060.	1.4	228
5	Mechanistic studies on aromatase and related C ₁₇ -C bond cleaving P-450 enzymes. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1993, 44, 375-387.	1.2	188
6	CYP17 inhibitors for prostate cancer therapy. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2011, 125, 23-31.	1.2	177
7	Promise and challenges in drug discovery and development of hybrid anticancer drugs. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 1099-1111.	2.5	164
8	Discovery and Development of Galeterone (TOK-001 or VN/124-1) for the Treatment of All Stages of Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 2077-2087.	2.9	164
9	Androgen receptor inactivation contributes to antitumor efficacy of 17 β -hydroxylase/17,20-lyase inhibitor 3 β -hydroxy-17-(1 <i>H</i> -benzimidazole-1-yl)androst-5,16-diene in prostate cancer. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2348-2357.	1.9	137
10	Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 4323-4340.	1.4	132
11	Novel 17-Azolyl Steroids, Potent Inhibitors of Human Cytochrome 17 β -Hydroxylase-C17,20-lyase (P45017 β): Potential Agents for the Treatment of Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 902-912.	2.9	117
12	Aromatase inhibitors and their application in breast cancer treatment. <i>Steroids</i> , 2000, 65, 171-179.	0.8	105
13	A New Simple and High-Yield Synthesis of Suberoylanilide Hydroxamic Acid and Its Inhibitory Effect Alone or in Combination with Retinoids on Proliferation of Human Prostate Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 5047-5051.	2.9	98
14	Systematic Structure Modifications of Multitarget Prostate Cancer Drug Candidate Galeterone To Produce Novel Androgen Receptor Down-Regulating Agents as an Approach to Treatment of Advanced Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4880-4898.	2.9	92
15	Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo. <i>Oncotarget</i> , 2015, 6, 27440-27460.	0.8	91
16	Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1998, 66, 1-10.	1.2	86
17	Three Dimensional Pharmacophore Modeling of Human CYP17 Inhibitors. Potential Agents for Prostate Cancer Therapy. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 2345-2351.	2.9	86
18	Competitive Antagonism between the Nicotinic Allosteric Potentiating Ligand Galantamine and Kynurenic Acid at α 7* Nicotinic Receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 322, 48-58.	1.3	77

#	ARTICLE	IF	CITATIONS
19	Comprehensive Pharmacology and Clinical Efficacy of Aromatase Inhibitors. <i>Drugs</i> , 1999, 58, 233-255.	4.9	75
20	Methyl Angolensate: The Antiulcer Agent of the Stem Bark of <i>Entandrophragma angolense</i> . <i>Planta Medica</i> , 1995, 61, 91-92.	0.7	70
21	Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2000, 75, 1-10.	1.2	67
22	Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): Head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model. <i>Steroids</i> , 2011, 76, 1268-1279.	0.8	67
23	17 β -Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2828-2836.	1.9	64
24	Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence <i>in vitro</i> . <i>Molecular Cancer Therapeutics</i> , 2008, 7, 121-132.	1.9	55
25	First Mnk3 degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines. <i>Oncotarget</i> , 2014, 5, 530-543.	0.8	52
26	4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesulfonate) (NSC 88915) and Related Novel Steroid Derivatives as Tyrosyl-DNA Phosphodiesterase (Tdp1) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 7122-7131.	2.9	50
27	Novel Retinoic Acid Metabolism Blocking Agents Endowed with Multiple Biological Activities Are Efficient Growth Inhibitors of Human Breast and Prostate Cancer Cells <i>In Vitro</i> and a Human Breast Tumor Xenograft in Nude Mice. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 6716-6729.	2.9	48
28	Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 3352-3360.	1.4	48
29	20-Amino and 20,21-aziridinyl pregnene steroids: Development of potent inhibitors of 17 β -hydroxylase/C17,20-lyase (P450 17). <i>Bioorganic and Medicinal Chemistry</i> , 1996, 4, 1447-1453.	1.4	42
30	Synthesis and evaluation of novel 17-indazole androstene derivatives designed as CYP17 inhibitors. <i>Steroids</i> , 2007, 72, 939-948.	0.8	42
31	Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1777-1793.	1.9	42
32	The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer. <i>Carcinogenesis</i> , 2013, 34, 199-210.	1.3	41
33	Nucleophilic vinylic α -addition-elimination α -substitution reaction of 3 β -acetoxy-17-chloro-16-formylandrosta-5,16-diene: A novel and general route to 17-substituted steroids. Part 1 - synthesis of novel 17-azolyl- β -16 steroids; inhibitors of 17 β -hydroxylase/17, 20-lyase (17 β -lyase). <i>Bioorganic and Medicinal Chemistry Letters</i> , 1996, 6, 2777-2782.	1.0	40
34	Galeterone and VNPT55 disrupt Mnk3-eIF4E to inhibit prostate cancer cell migration and invasion. <i>FEBS Journal</i> , 2016, 283, 3898-3918.	2.2	39
35	Design, Synthesis, and Evaluation of Novel Mutual Prodrugs (Hybrid Drugs) of All- <i>trans</i> -Retinoic Acid and Histone Deacetylase Inhibitors with Enhanced Anticancer Activities in Breast and Prostate Cancer Cells <i>In Vitro</i> . <i>Journal of Medicinal Chemistry</i> , 2008, 51, 3895-3904.	2.9	37
36	Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 166, 16-27.	1.2	35

#	ARTICLE	IF	CITATIONS
37	Antifertility Activity of Quassia amara: Quassin Inhibits the Steroidogenesis in Rat Leydig Cells In Vitro. <i>Planta Medica</i> , 1995, 61, 180-182.	0.7	34
38	High-Yield Synthesis of Novel Imidazoles and Triazoles from Alcohols and Phenols. <i>Synthesis</i> , 2000, 2000, 2019-2028.	1.2	33
39	Novel, potent anti-androgens of therapeutic potential: recent advances and promising developments. <i>Future Medicinal Chemistry</i> , 2010, 2, 667-680.	1.1	33
40	The retinamide VNLG-152 inhibits AR and MNK-4E signaling pathways to suppress EMT and castration-resistant prostate cancer xenograft growth. <i>FEBS Journal</i> , 2018, 285, 1051-1063.	2.2	33
41	Synthesis of 6-hydroximino-3-oxo steroids, a new class of aromatase inhibitor. <i>Journal of the Chemical Society Perkin Transactions 1</i> , 1992, , 585.	0.9	32
42	2-Methoxycanthin-6-one: A New Alkaloid from the Stem Wood of Quassia amara. <i>Planta Medica</i> , 1993, 59, 259-261.	0.7	32
43	Novel C-4 Heteroaryl 13-cis-Retinamide Mnk/AR Degrading Agents Inhibit Cell Proliferation and Migration and Induce Apoptosis in Human Breast and Prostate Cancer Cells and Suppress Growth of MDA-MB-231 Human Breast and CWR22Rv1 Human Prostate Tumor Xenografts in Mice. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 1900-1914.	2.9	31
44	Cytochrome P450c17-Expressing Escherichia colias a First-Step Screening System for 17 β -Hydroxylase-C17,20-lyase Inhibitors. <i>Analytical Biochemistry</i> , 1999, 267, 319-330.	1.1	28
45	The Coffey Lecture: Steroidogenic enzyme inhibitors and hormone dependent cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 53-63.	0.8	28
46	Effects of Novel Retinoic Acid Metabolism Blocking Agent (VN/14-1) on Letrozole-Insensitive Breast Cancer Cells. <i>Cancer Research</i> , 2006, 66, 11485-11493.	0.4	27
47	First pharmacophore-based identification of androgen receptor down-regulating agents: Discovery of potent anti-prostate cancer agents. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 3413-3421.	1.4	27
48	Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 3519-3529.	1.4	27
49	Potent inhibition of retinoic acid metabolism enzyme(s) by novel azolyl retinoids. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2000, 10, 1905-1908.	1.0	25
50	Synthesis of novel C17 steroidal carbamates. <i>Steroids</i> , 2008, 73, 1217-1227.	0.8	25
51	Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines. <i>Oncotarget</i> , 2015, 6, 3195-3210.	0.8	25
52	Transcriptome profiling reveals that VNPP433-12, the lead next-generation galeterone analog inhibits prostate cancer stem cells by downregulating epithelial-mesenchymal transition and stem cell markers. <i>Molecular Carcinogenesis</i> , 2022, 61, 643-654.	1.3	25
53	Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2004, 92, 155-165.	1.2	23
54	Targeting of protein translation as a new treatment paradigm for prostate cancer. <i>Current Opinion in Oncology</i> , 2017, 29, 210-220.	1.1	20

#	ARTICLE	IF	CITATIONS
55	Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3 β Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo. <i>Cancers</i> , 2019, 11, 1637.	1.7	20
56	Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3 β -Imidazole Carbamate. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 708-713.	1.3	19
57	Autophagy Inhibition Synergistically Enhances Anticancer Efficacy of RAMBA, VN/12-1 in SKBR-3 Cells, and Tumor Xenografts. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 898-908.	1.9	18
58	The Novel Mnk1/2 Degradator and Apoptosis Inducer VNLG-152 Potently Inhibits TNBC Tumor Growth and Metastasis. <i>Cancers</i> , 2019, 11, 299.	1.7	18
59	Synthesis of novel 21-trifluoropregnane steroids: Inhibitors of 17 β -hydroxylase/17,20-lyase (17 β -lyase). <i>Steroids</i> , 1997, 62, 468-473.	0.8	17
60	First chemical feature-based pharmacophore modeling of potent retinoidal retinoic acid metabolism blocking agents (RAMBAs): Identification of novel RAMBA scaffolds. <i>European Journal of Medicinal Chemistry</i> , 2012, 47, 412-423.	2.6	15
61	Galeterone and its analogs inhibit Mnk-eIF4E axis, synergize with gemcitabine, impede pancreatic cancer cell migration, invasion and proliferation and inhibit tumor growth in mice. <i>Oncotarget</i> , 2017, 8, 52381-52402.	0.8	14
62	Retinoids in Clinical Use. <i>Medicinal Chemistry</i> , 2006, 2, 431-438.	0.7	12
63	A new simple and high-yield synthesis of 5 α -dihydrotestosterone (DHT), a potent androgen receptor agonist. <i>Steroids</i> , 2012, 77, 1530-1534.	0.8	11
64	Concerning the pathway from 19-oxoandrost-4-ene-3,17-dione to estrone. <i>Steroids</i> , 1987, 50, 347-362.	0.8	10
65	Synthesis of 10 β -(1 α -azirinyloxy)estr-4-en-3,17-dione as an aromatase inhibitor. <i>Steroids</i> , 1996, 61, 138-143.	0.8	10
66	Novel galeterone analogs act independently of AR and AR-V7 for the activation of the unfolded protein response and induction of apoptosis in the CWR22Rv1 prostate cancer cell model. <i>Oncotarget</i> , 2017, 8, 88501-88516.	0.8	10
67	Evaluation of 6,7-Aziridinyloxy Steroids and Related Compounds as Inhibitors of Aromatase (P-450arom). <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 1995, 9, 195-202.	0.5	9
68	New Insights into the Androgen-Targeted Therapies and Epigenetic Therapies in Prostate Cancer. <i>Prostate Cancer</i> , 2011, 2011, 1-13.	0.4	9
69	Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 899-905.	1.1	8
70	Improved Procedures for Gram-Scale Synthesis of Galeterone 3 β -Imidazole and Galeterone 3 β -Pyridine Methoxylate, Potent Androgen Receptor/Mnk Degrading Agents. <i>Organic Process Research and Development</i> , 2016, 20, 1654-1661.	1.3	8
71	Development of Benzimidazole Compounds for Cancer Therapy. , 0, , .		8
72	Novel deuterated Mnk1/2 protein degrader VNLG-152R analogs: Synthesis, In vitro Anti-TNBC activities and pharmacokinetics in mice. <i>European Journal of Medicinal Chemistry</i> , 2022, 238, 114441.	2.6	7

#	ARTICLE	IF	CITATIONS
73	VN/14-1 induces ER stress and autophagy in HP-LTLC human breast cancer cells and has excellent oral pharmacokinetic profile in female Sprague Dawley rats. <i>European Journal of Pharmacology</i> , 2014, 734, 98-104.	1.7	6
74	Quantification of a novel retinoic acid metabolism inhibitor, 4-(1H-imidazol-1-yl)retinoic acid (VN/14-1RA) and other retinoids in rat plasma by liquid chromatography with diode-array detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 810, 203-208.	1.2	6
75	Quantification of a novel retinoic acid metabolism inhibitor, 4-(1H-imidazol-1-yl)retinoic acid (VN/14-1RA) and other retinoids in rat plasma by liquid chromatography with diode-array detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 810, 203-208.	1.2	5
76	Pharmacokinetics of novel inhibitors of androgen synthesis after intravenous administration in mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 51, 519-524.	1.1	4
77	Murine toxicology and pharmacokinetics evaluation of retinoic acid metabolism blocking agent (RAMBA), VN/12-1. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 339-344.	1.1	4
78	Anti-tumor effects of a novel retinoic acid metabolism blocking agent VN/14-1 in the N-methyl-N-nitrosourea-induced rat mammary carcinoma model and its effects on the uterus. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 137-144.	1.1	4
79	Large-scale synthesis of galeterone and lead next generation galeterone analog VNPP433-3 ¹² . <i>Steroids</i> , 2022, 185, 109062.	0.8	4
80	Synthesis of C-2, 3, 17 and 19-oxygenated androgens. <i>The Journal of Steroid Biochemistry</i> , 1988, 29, 353-359.	1.3	3
81	Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo. <i>Cancers</i> , 2020, 12, 3412.	1.7	3
82	Prostate Cancer: Current and Emerging Therapies. , 2011, , .		1
83	Letter to the editor. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 9-10.	1.5	1
84	Abstract 1764: Galeterone and its novel analogs induce profound anti-cancer activities in human pancreatic cancer cell lines: Implications for pancreatic cancer therapy. , 2015, , .		1
85	Androgen receptor antagonism and impact on inhibitors of androgen synthesis in prostate cancer therapy. <i>Translational Cancer Research</i> , 2017, 6, S1128-S1131.	0.4	1
86	Galeterone to target proteasomal degradation of the androgen receptor in prostate tumor cells: A novel mechanism of action for treatment of AR-V7+ CRPC.. <i>Journal of Clinical Oncology</i> , 2016, 34, e14092-e14092.	0.8	0